<DOC>
	<DOCNO>NCT00026286</DOCNO>
	<brief_summary>RATIONALE : Hormone replacement therapy may effective manage hot flash and/or vaginal symptom postmenopausal woman receive tamoxifen breast cancer . PURPOSE : Randomized phase III trial determine effectiveness hormone replacement therapy manage hot flash and/or vaginal symptom postmenopausal woman receive tamoxifen breast cancer .</brief_summary>
	<brief_title>Hormone Replacement Therapy Hot Flashes and/or Vaginal Symptoms Postmenopausal Women Receiving Tamoxifen Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy hormone replacement therapy manage hot flash menopausal vaginal symptom postmenopausal woman history node-negative invasive carcinoma ductal carcinoma situ breast receive adjuvant tamoxifen . - Determine effect regimen blood coagulation lipid profile patient . - Determine quality life patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord prior hysterectomy ( yes v ) , symptom complex ( vasomotor v vaginal v ) , duration hot flash ( less 1 year hot flash vs 1 year ) , average daily number hot flash ( less 10 none v 10 ) . Patients randomize one two treatment arm . - Arm I : Patients undergo prior hysterectomy receive oral medroxyprogesterone daily 6 month . If , 1 month , symptom resolve , patient receive oral conjugate estrogen daily addition medroxyprogesterone 5 month . Patients undergone prior hysterectomy receive oral conjugate estrogen daily 6 month . - Arm II : Patients receive oral placebo daily 6 month . Quality life assess baseline month 1 , 2 , 3 , 6 . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 120 patient ( 60 per treatment arm ) accrue study within 12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nodenegative invasive carcinoma ductal carcinoma situ breast No contralateral breast cancer No recurrent metastatic disease Completion active nonhormonal therapy breast cancer Receiving tamoxifen ( 20 mg/day ) least 3 month prior study plan continue drug study Hot flash severe enough seek medical intervention ( least 78 moderate severe hot flash per day 60 per week baseline ) AND/OR Vaginal symptom , include dyspareunia , vaginal dryness , irritation , thin due estrogen deficiency If uterus present , prior histologically confirm adenomatous atypical endometrial hyperplasia endometrial carcinoma AND concurrent endometrial cancer confirm pelvic exam within past year No active endometriosis No unexplained vaginal bleed Hormone receptor status : Estrogen progesterone receptor status know patient invasive breast cancer PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Postmenopausal No menstrual period 12 month OR prior bilateral oophorectomy Must 55 year age OR document folliclestimulating hormone level postmenopausal range one ovary remain prior hysterectomy Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No prior superficial deep venous arterial thrombosis No serious venous stasis disease Pulmonary : No pulmonary embolus Other : Must able read speak English No low extremity trauma , swell , tenderness within past 4 week No active gallbladder disease No migraine headaches No prior malignancy unless curatively treat evidence recurrence No concurrent seizure disorder require antiseizure medication PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics No concurrent estrogen hormone replacement therapy No concurrent clonidine , bellergal , progestational agent , methyldopa hot flash No concurrent topical vaginal estrogen cream ( e.g. , Estring Vagifem ) patient vaginal symptom Radiotherapy : Not specify Surgery : At least 4 week since prior surgery Other : At least 12 month since prior treatment congestive heart failure Concurrent selective serotonin reuptake inhibitor ( SSRI ) antidepressants SSRI activity allow begin least 3 month prior study continue study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>ductal breast carcinoma</keyword>
	<keyword>hot flash</keyword>
	<keyword>menopausal symptom</keyword>
</DOC>